Clinical trials: Muscle Disorders
Multiple Sclerosis, Spasticity, Muscle
Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain
The study is a 4-week double-blind, randomized, controlled, parallel design investigation to investigate the impact of intermittent negative pressure on spasticity and pain in people with multiple sclerosis (pwMS).
- Conditions
- Multiple Sclerosis, Spasticity, Muscle, Pain, Chronic
- Trial name
- FO-NP002 (NCT05562453)
- Testing
- FlowOx 2.0
- Where
- Sweden
- Volunteers
- 56 people
- Sponsor
- Otivio AS
Muscular Atrophy, Spinal
A Study of the Safety of Nusinersen (Spinraza®) and Its Effects on Motor Function in Koreans Living With SMA Treated During Their Usual Medical Care
In this study, researchers will learn more about the effects of nusinersen, also known as Spinraza®, in Korean participants with spinal muscular atrophy, also known as SMA.
- Trial name
- STANDARD (NCT04317794)
- Testing
- Nusinersen Sodium Injection
- Where
- 16 sites in South Korea
- Volunteers
- 74 people
- Sponsor
- Biogen
Shoulder Pain, Neck Pain
Low Level Laser Light Therapy and Chronic Neck and Shoulder Pain
The purpose of this study was to determine whether the application of low level laser light therapy to the neck and shoulder region is effective in reducing chronic neck and shoulder pain of musculoskeletal origin.
- Conditions
- Shoulder Pain, Neck Pain, Musculoskeletal Pain, Musculoskeletal Strain
- Trial name
- NCT00929305
- Testing
- Erchonia PL2000
- Volunteers
- 100 people
- Sponsor
- Erchonia Corporation
Primary Fibromyalgia
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
This is a Phase 3, open-label, extension trial designed to evaluate the long term safety and efficacy over 3 months of TNX-102 SL tablets taken daily at bedtime for the treatment of Fibromyalgia (FM).
- Trial name
- NCT02589275
- Testing
- TNX-102 SL Tablet 2.8 mg
- Where
- 33 sites in United States
- Volunteers
- 375 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Fibromyalgia
Fibromyalgia Health Outcome Study on Cost of Treatments
The Real World Examination of Fibromyalgia: Longitudinal Evaluation of Costs and Treatments (REFLECTIONS) Study is a 12-month, prospective observational study that will be utilized in approximately 58 care settings in the United…
- Trial name
- REFLECTIONS (NCT00725101)
- Testing
- Treatment for Fibromyalgia
- Where
- 58 sites in United States, Puerto Rico
- Volunteers
- 1,700 people
- Sponsor
- Eli Lilly and Company
Muscular Dystrophy, Duchenne
Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy
The study will evaluate the safety and dystrophin expression following gene therapy in boys with Duchenne Muscular Dystrophy (DMD). It is a single-arm, non-randomized, open-label study
- Trial name
- NCT05429372
- Testing
- PF-06939926
- Where
- 13 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Pfizer
Multiple Sclerosis
IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis
The purpose of this study is to determine the effects, both good and bad, of IPX056 on subjects and their spasticity. This study will also determine the relationship between the amount of IPX056 in blood and the effects on…
- Trial name
- NCT00488839
- Testing
- IPX056 20 mg, IPX056 40 mg, Encapsulated Baclofen 20 mg
- Where
- 31 sites in United States, Canada and 3 more
- Volunteers
- 173 people
- Sponsor
- Impax Laboratories, LLC
Fibromyalgia Syndrome
Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.
This trial investigated the efficacy and safety of 400mg/day of lacosamide as compared to placebo in reducing the signs and symptoms of fibromyalgia syndrome.
- Trial name
- NCT00401830
- Testing
- Lacosamide
- Where
- 25 sites in United States
- Volunteers
- 159 people
- Sponsor
- UCB Pharma
Duchenne Muscular Dystrophy
Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)
The main objective of this study is to evaluate the efficacy of Viltolarsen compared to placebo in Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping.
- Trial name
- NCT04060199
- Testing
- Viltolarsen
- Where
- 40 sites in United States, Australia and 17 more
- Volunteers
- 77 people
- Sponsor
- NS Pharma, Inc.
Fibrodysplasia Ossificans Progressiva
An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO) often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to…
- Trial name
- MOVE (NCT03312634)
- Testing
- Palovarotene
- Where
- 16 sites in United States, Argentina and 9 more
- Volunteers
- 107 people
- Sponsor
- Clementia Pharmaceuticals Inc.
Cancer
Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells
A retrospective, observational study conducted on cancer patients receiving a drug that blocks certain proteins made by some types of immune system cells
- Trial name
- NCT03644498
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 1,056 people
- Sponsor
- Bristol-Myers Squibb
Sarcopenia, Back Pain
The "Free From Pain Exercise Book" Versus "The Back Book".
This pragmatic randomised control feasibility trial aims to investigate the effectiveness of the "Free From Pain Exercise Book" in comparison to "The Back Book" for reducing back pain in adults aged 60 and over.
- Conditions
- Sarcopenia, Back Pain, Arthritis
- Trial name
- NCT05359107
- Testing
- "The Free From Pain Exercise Book", "The Back Book"
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Talita Cumi Ltd.
Fibromyalgia
Study of Milnacipran for the Treatment of Fibromyalgia
The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia.
- Trial name
- NCT00314249
- Testing
- Milnacipran 100mg
- Where
- 24 sites in United States
- Volunteers
- 1,025 people
- Sponsor
- Forest Laboratories
Duchenne Muscular Dystrophy
Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy
This is a Phase 1, double-blind, placebo-controlled, single ascending dose cohort study to evaluate the safety, tolerability, and plasma concentrations of WVE-210201 in ambulatory and non-ambulatory male pediatric patients with…
- Trial name
- NCT03508947
- Testing
- WVE-210201
- Where
- 13 sites in United States, Belgium and 5 more
- Volunteers
- 36 people
- Sponsor
- Wave Life Sciences USA, Inc.
Lateral Epicondylitis, (Tennis Elbow)
Dexamethasone Iontophoretic Patch for the Treatment of Pain Associated With Lateral Epicondylitis
The objective of this study is to determine the safety and efficacy of a dexamethasone iontophoretic transdermal patch for the treatment of pain associated with lateral epicondylitis (tennis elbow).
- Trial name
- NCT00794976
- Testing
- Dexamethasone Iontophoretic Patch (low dose), Dexamethasone Iontophoretic Patch (high dose), Dexamethasone Passive Patch
- Where
- 10 sites in United States
- Volunteers
- 216 people
- Sponsor
- Travanti Pharma Inc.
Bladder Cancer
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
This is an international, multicenter, double-blind, placebo-controlled, randomized study. All eligible patients entering the open label phase of the study will receive a single immediate instillation of apaziquone (4 mg in 40 mL…
- Trial name
- NCT01469221
- Testing
- Apaziquone
- Where
- 29 sites in United States, Czechia and 2 more
- Volunteers
- 47 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Duchenne Muscular Dystrophy
Study of UC-MSC in DMD Patients
The primary objective of this study is to provide UC-MSC treatment to patients with DMD. Secondary objectives will be to further evaluate treatment-related adverse events as well as changes in DMD-related functional…
- Trial name
- NCT06579352
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC)
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- MED Institute Inc.
Spasticity
Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity
This is a randomized, double-blind, placebo-controlled single ascending dose escalation study intended to assess the safety, pharmacokinetics and efficacy of single treatment of SL-1002 in patients with mild to severe limb…
- Trial name
- RAISE (NCT05311215)
- Testing
- SL-1002
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Saol Therapeutics Inc
Major Depressive Disorder, Fibromyalgia
Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
The primary objective of this study is to provide duloxetine to investigators for the treatment of patients who have previously participated in neuroscience duloxetine clinical trials and for whom effective alternative therapy is…
- Conditions
- Major Depressive Disorder, Fibromyalgia, Diabetic Peripheral Neuropathic Pain, Generalized Anxiety Disorder
- Trial name
- NCT00071708
- Testing
- Duloxetine Hydrochloride
- Where
- 13 sites in Australia
- Sponsor
- Eli Lilly and Company
Target Drug-related Adverse Events
Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens
The purpose of this study is to determine whether the addition of selective pharmacogenomic (PGx) testing as determined by Urine Drug Testing (UDT) adds a clinical benefit as evidenced by a reduction in Target Drug-related…
- Trial name
- SPHERE (NCT02625155)
- Testing
- Urine diagnostic testing as SOC, drug regimen changes per SOC, Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results
- Where
- United States
- Volunteers
- 14,000 people, healthy volunteers welcome
- Sponsor
- InSource Diagnostics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.